The absence of polymorphisms in ADRB3, UCP1, PPARγ, and ADIPOQ genes protects morbid obese patients toward insulin resistance
The absence of polymorphisms in ADRB3, UCP1, PPARγ, and ADIPOQ genes protects morbid obese patients toward insulin resistance
复制标题
DOI：
10.1007/bf03345413
复制
发表时间：
2012-01-01
影响因子：
5.4
通讯作者：
Pasanisi, F.
中科院分区：
文献类型：
--
作者：
Bracale, R.;Labruna, G.;Pasanisi, F.
背景和目标：胰岛素抵抗（IR）是严重肥胖症的主要代谢障碍，是一种多因素疾病，单核苷酸多态性（SNP）在不同基因而非单个基因中的作用已被证实。本研究的目的是测试β 3-肾上腺素能受体（ADRB 3），解偶联蛋白1（UCP 1），过氧化物酶体增殖物激活受体γ（PPAR γ）和脂联素（ADIPOQ）基因多态性/变异的存在/不存在对诊断肥胖IR的预测价值。研究对象和方法：我们研究了112名（40名男性，72名女性）严重肥胖（体重指数：48.5 +/- 7.5 kg/m2）的受试者，他们是从那不勒斯费德里科二世大学医院的肥胖门诊招募的。用市售试剂盒从外周血白细胞中提取基因组DNA。采用TaqMan法或直接测序法（ADIPOQ）对ADRB 3基因Trp 64 Arg多态性、UCP 1基因-3826 A>G多态性、PPAR γ基因Pro 12 Ala多态性和ADIPOQ基因c.268G>A、c.331T>C、c.334C>T多态性进行分析。结果与结论：UCP 1基因-3826A>G多态性与肥胖症胰岛素抵抗相关。此外，缺乏任何多态性，ADRB 3中的Trp 64 Arg和/或UCP 1中的-3826 A>G和/或PPAR γ中的Pro 12 Ala和/或ADIPOQ中的c.268 G>A、c.331 T>C和c.334 C>T，似乎是这些肥胖患者中IR发作的有用预后因素（NPV=100%），代表了早期和适当治疗的进一步参数。(J.年. Invest. 35：2-4，2012）2012，Editrice Kurtis
Background and aims: The insulin resistance (IR) is a major metabolic impairment in severe obesity, a multifactorial disease in which the importance of the effect of single nucleotide polymorphisms (SNP) associations in different rather than individual genes was established. The aim of this study was to test the predictive value of presence/absence of polymorphisms/variants in beta 3-adrenergic receptor (ADRB3), uncoupling protein 1 (UCP1), peroxisome proliferator-activated receptor gamma (PPAR gamma), and adiponectin (ADIPOQ) genes in diagnosing the IR in obesity. Subjects and methods: We studied 112 (40 males, 72 females) severely obese (body mass index: 48.5 +/- 7.5 kg/m(2))subjects recruited from the outpatient obesity clinic of Federico II University Hospital in Naples. Genomic DNA was extracted from peripheral leukocytes with a commercial kit. The gene polymorphisms Trp64Arg in ADRB3, -3826 A>G in UCP1, Pro12Ala in PPAR gamma, and c.268G>A, c.331T>C, and c.334C>T in ADIPOQ were characterized by TaqMan assay or by direct sequencing (ADIPOQ). Results and conclusion: Our results demonstrate that -3826A>G UCP1 polymorphism is associated with IR in morbid obesity. Further, the lack of any polymorphisms, Trp64Arg in ADRB3 and/or -3826 A>G in UCP1 and/or Pro12Ala in PPAR gamma and/or c.268G>A, c.331T>C and c.334C>T in ADIPOQ, appears a useful prognostic factor (NPV=100%) toward the IR onset in these obese patients representing a further parameter for an earlier and appropriate therapy. (J. Endocrinol. Invest. 35: 2-4, 2012) 2012, Editrice Kurtis